U.S. FDA Approves VYALEV™ (Foscarbidopa and Foslevodopa) for Adults Living with Advanced Parkinson’s Disease
VYALEV™ is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy for the treatment of motor fluctuations in advanced Parkinson’s disease Adults treated with VYALEV reported superior improvement in “on”… Read More



